HDAC4 Inhibitors as Antivascular Senescence Therapeutics.
Chunxue BaiZhongxiao LinXiaoyan LiuQian DingJianghong CaiZhongyi ZhangPeter RoseYi Zhun ZhuPublished in: Oxidative medicine and cellular longevity (2022)
Aging is an inevitable consequence of life, and during this process, the epigenetic landscape changes and reactive oxygen species (ROS) accumulation increases. Inevitably, these changes are common in many age-related diseases, including neurodegeneration, hypertension, and cardiovascular diseases. In the current research, histone deacetylation 4 (HDAC4) was studied as a potential therapeutic target in vascular senescence. HDAC4 is a specific class II histone deacetylation protein that participates in epigenetic modifications and deacetylation of heat shock proteins and various transcription factors. There is increasing evidence to support that HDAC4 is a potential therapeutic target, and developments in the synthesis and testing of HDAC4 inhibitors are now gaining interest from academia and the pharmaceutical industry.
Keyphrases
- histone deacetylase
- dna methylation
- reactive oxygen species
- heat shock
- dna damage
- cardiovascular disease
- gene expression
- transcription factor
- blood pressure
- endothelial cells
- cell death
- type diabetes
- small molecule
- human health
- risk assessment
- stress induced
- heat stress
- binding protein
- protein protein
- cardiovascular risk factors
- amino acid